drugset / Trial / NCT01887301
Assessment of the Single Dose Pharmacokinetics and Tolerability of Sativex in Patients With Impaired Hepatic Function and Healthy Patients
Non-randomizedParallel-groupOpen-labelTreatment
Summary
A Phase I open-label study to evaluate the pharmacokinetics (what the body does to a drug), safety and tolerability of a single dose of Sativex (containing 10.8 mg tetrahydrocannabinol \[THC\] and 10 mg cannabidiol \[CBD\]) in healthy patients and those with hepatic (liver) function impairment.
Timeline
- Start
- 2013-07
- Primary completion
- 2014-05
- Completion
- 2014-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nabiximols | Other / unclassified | 10 mg | Other |
| Subject | Nabiximols | Other / unclassified | 10.8 mg | Other |
Indications
No indication recorded.